Cigna Expands Coverage of Glaucoma Surgical Procedures to Include Canaloplasty and Goniotomy (Trabeculotomy)
21 Junho 2023 - 9:30AM
Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or
the “Company”), an eyecare technology company focused on
developing and commercializing innovative technology intended to
transform care and improve patients' lives, announced today that
Cigna Healthcare (“Cigna”), has updated its Glaucoma Surgical
Procedure policy to cover both ab interno canaloplasty and
goniotomy (trabeculotomy) procedures for the treatment of
open-angle glaucoma effective June 15, 2023.
Cigna is one of the largest health insurance companies in the
United States with close to 15 million covered lives. The OMNI
Surgical System (“OMNI”) technology is FDA-cleared and indicated
for canaloplasty followed by trabeculotomy to reduce intraocular
pressure (“IOP”) in adult patients with primary open-angle
glaucoma. OMNI technology enables the surgeon to perform an outflow
restorative procedure to address the three known points of aqueous
resistance associated with glaucoma (Schlemm’s canal, collector
channels, and trabecular meshwork). The procedure can be performed
before, in combination with, or after cataract surgery.
“We are pleased that Cigna’s clinical review resulted in
expanded coverage of certain non-implant, minimally invasive
glaucoma surgery (“MIGS”) procedures including canaloplasty and
goniotomy for its patients,” stated Paul Badawi, Founder and Chief
Executive Officer. “As a result of this positive coverage policy,
Cigna’s members will have access to the OMNI outflow restorative
procedure that addresses all three points of resistance when deemed
medically necessary by their ophthalmologist. We believe Cigna’s
decision affirms the shift towards safer, less invasive, but more
comprehensive surgical inventions, and cements the role that OMNI’s
technology serves within the glaucoma treatment paradigm for
surgeons and patients.”
Data evidencing the effectiveness and safety of OMNI have been
published in 18 peer-reviewed publications, representing more than
630 patients to date, including two landmark multicenter studies,
GEMINI and ROMEO. More recently real-world data leveraging the
American Academy of Ophthalmology’s IRIS® Registry was presented at
the 2023 American Society of Cataract and Refractive Surgery and
the American Glaucoma Society Annual Meetings, where a 12-month
sub-analysis of patients treated with OMNI Surgical System
technology reported the greatest average reduction in IOP-lowering
medication usage compared to implant-based MIGS procedures or
cataract surgery alone.
“We are pleased that Cigna has expanded coverage and increased
patient access to more minimally invasive glaucoma surgeries,”
stated Elena Sturman, President and CEO of The Glaucoma Foundation,
one of the nation’s leading foundations dedicated to improving the
lives of patients with glaucoma through innovation, research and
collaboration. She continued, “Glaucoma is the leading cause of
irreversible blindness in the United States. Improving access to
less invasive outflow restorative procedures (associated with OMNI
technology) is an important addition for glaucoma patients.”
Cigna Healthcare’s updated Glaucoma Surgical Procedures policy
can be found here:
https://static.cigna.com/assets/chcp/pdf/coveragePolicies/medical/mm_0035_coveragepositioncriteria_viscocanolostomy.pdf
About Sight SciencesSight Sciences is an
eyecare technology company focused on developing and
commercializing innovative solutions intended to transform care and
improve patients’ lives. Using minimally invasive or non-invasive
approaches to target the underlying causes of the world’s most
prevalent eye diseases, Sight Sciences seeks to create more
effective treatment paradigms that enhance patient care and
supplant conventional outdated approaches. The Company’s OMNI
Surgical System is an implant-free glaucoma surgery technology
indicated to reduce intraocular pressure in adult patients with
primary open-angle glaucoma (POAG), the world’s leading cause of
irreversible blindness. The Company’s TearCare® System technology
is 510(k) cleared for the application of localized heat therapy in
adult patients with evaporative dry eye disease due to meibomian
gland dysfunction (MGD), enabling clearance of gland obstructions
by physicians to address the leading cause of dry eye disease. The
Company’s SION™ Surgical Instrument is a manually operated device
used in ophthalmic surgical procedures to excise trabecular
meshwork.
For more information, visit http://www.sightsciences.com.
OMNI and TearCare are registered trademarks of Sight Sciences.
SION is a trademark of Sight Sciences.© 2023 Sight Sciences. All
rights reserved.
Forward-Looking StatementsThis press release,
together with other statements and information publicly
disseminated by the Company, contains certain forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. The Company intends such forward-looking
statements to be covered by the safe harbor provisions for
forward-looking statements contained in the Private Securities
Litigation Reform Act of 1995 and includes this statement for
purposes of complying with these safe harbor provisions. Any
statements made in this press release or during the earnings call
that are not statements of historical fact, including statements
about our beliefs and expectations, are forward-looking statements
and should be evaluated as such. Forward-looking statements include
statements regarding increased access to the OMNI outflow
restorative procedure, and other perceived benefits of Cigna’s
coverage determination. These statements often include words such
as “anticipate,” “expect,” “suggests,” “plan,” “believe,” “intend,”
“estimates,” “targets,” “projects,” “should,” “could,” “would,”
“may,” “will,” “forecast” and other similar expressions. We base
these forward-looking statements on our current expectations, plans
and assumptions that we have made in light of our experience in the
industry, as well as our perceptions of historical trends, current
conditions, expected future developments and other factors we
believe are appropriate under the circumstances at such time.
Although we believe that these forward-looking statements are based
on reasonable assumptions at the time they are made, you should be
aware that many factors could affect our business, results of
operations and financial condition and could cause actual results
to differ materially from those expressed in the forward-looking
statements. These forward-looking statements are subject to and
involve numerous risks, uncertainties and assumptions, including
those discussed under the caption “Risk Factors” in our filings
with the U.S. Securities and Exchange Commission, as may be updated
from time to time in subsequent filings, and you should not place
undue reliance on these statements. These cautionary statements are
made only as of the date of this press release. We undertake no
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise,
except as required by applicable law.
Media contact – Glaucoma:Carmen CaricchioC2M
Grouppr@SightSciences.com
Investor contact:Philip TaylorGilmartin
Group415.937.5406Investor.Relations@Sightsciences.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/857d6e32-e989-40d0-b5b4-4e1b43406bb4
Sight Sciences (NASDAQ:SGHT)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Sight Sciences (NASDAQ:SGHT)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024